• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications.

作者信息

van Aalderen W, van Seters A P, Backer E T, Chang P C, van Krieken J H, Moolenaar A J

机构信息

Diaconessenhuis, Leiden, Netherlands.

出版信息

Neth J Med. 1992 Oct;41(3-4):161-70.

PMID:1470288
Abstract

This report describes a patient with a recurring, one stemline-aneuploid, adrenocortical carcinoma. The condition showed a number of unusual characteristics over a period of 22 yr. It changed from a biochemically functioning, low-grade malignant tumour into a non-functioning malignancy with pronounced mitotic activity, accompanied by an ovarian carcinosarcoma 1 yr before death. Quality of life was reasonable for many years despite chemotherapy, consisting of a total of almost 10 kg of o,p'-DDD administered over a period of 8 yr, and the subsequent side effects (e.g. low T4; increased bleeding time). A reduced mineralocorticoid activity, induced by o,p'-DDD, was reversed after discontinuation of o,p'-DDD treatment. During o,p'-DDD administration the substitution requirements for both hydrocortisone and fludrocortisone acetate increased, leading to periods of hypoadrenocorticism with prerenal uraemia.

摘要

相似文献

1
A case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications.
Neth J Med. 1992 Oct;41(3-4):161-70.
2
Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.血浆米托坦及其代谢物水平测定在肾上腺癌患者中的临床作用:长期随访结果
J Exp Ther Oncol. 2005;5(2):125-32.
3
Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD.
Exp Clin Endocrinol. 1994;102(1):50-3. doi: 10.1055/s-0029-1211265.
4
Adrenocortical carcinoma.肾上腺皮质癌
Am Surg. 1991 Aug;57(8):502-13.
5
[Favorable outcome of a recurring malignant adrenocortical tumor under O,P'-DDD therapy].
Ann Pediatr (Paris). 1985 Jun;32(6):541-4.
6
Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.米托坦增强了放疗抑制作用,并在联合治疗中诱导H295R和SW13肾上腺皮质细胞系出现G2期阻滞。
Endocr Relat Cancer. 2008 Jun;15(2):623-34. doi: 10.1677/erc.1.1315.
7
Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.米托坦在肾上腺皮质癌辅助治疗 H295R 异种移植模型中的作用。
Horm Metab Res. 2010 Sep;42(10):725-30. doi: 10.1055/s-0030-1261923. Epub 2010 Jul 27.
8
Chiral effects in adrenocorticolytic action of o,p'-DDD (mitotane) in human adrenal cells.
Xenobiotica. 2010 Mar;40(3):177-83. doi: 10.3109/00498250903470230.
9
Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?低剂量米托坦(邻,对'-滴滴滴)作为肾上腺皮质癌辅助治疗手段是否有作用?
J Clin Endocrinol Metab. 1998 Sep;83(9):3100-3. doi: 10.1210/jcem.83.9.5113.
10
Adrenocortical carcinoma--diagnostic and therapeutical implications.肾上腺皮质癌——诊断与治疗意义
Eur J Surg. 1993 Mar;159(3):149-58.

引用本文的文献

1
Actual 10-year survivors following resection of adrenocortical carcinoma.肾上腺皮质癌切除术后的实际10年幸存者。
J Surg Oncol. 2016 Dec;114(8):971-976. doi: 10.1002/jso.24439. Epub 2016 Sep 16.